Table 1.
Current licensed vaccines in the United States and Europe
| Region | Vaccine technology/platform | Vaccine type | Vaccine name (manufacturer) | Target/MOA | Adjuvant used |
|---|---|---|---|---|---|
| United States | Inactivated virus | Split virus | Afluria (Seqirus) | HAI | None |
| Fluarix (GSK) | HAI | None | |||
| FluLavel (GSK) | HAI | None | |||
| Fluzone, Fluzone HD (Sanofi Pasteur) | HAI | None | |||
| Fluad (Seqirus) | HAI | None | |||
| Subunit | Fluvirin (CLS Limited) | HAI | None | ||
| Flucelvax (Novartis) | HAI | None | |||
| Live-attenuated | Live, cold-adapted | FluMist (AstraZeneca) | HAI | None | |
| Recombinant protein | Non-purified HA | FluBlok (Sanofi Pasteur) | HAI | None | |
| Europe | Inactivated virus | Split virus | Influvac, Imuvac (Abbot) | HAI | None |
| Fluarix, Alpharix, Influsplit (GSK) | HAI | None | |||
| 3Fluart (Omninvest) | HAI | Alum | |||
| Afluria, Enzira (Pfizer/CSL) | HAI | None | |||
| Vaxigrip, Vaxigrip Tetra (Sanofi Pasteur) | HAI | None | |||
| Subunit | Agrippal (Seqirus) | HAI | None | ||
| Fluad (Seqirus) | HAI | MF59 | |||
| Live-attenuated | Live, cold-adapted | Fluenz Tetra (AstraZeneca) | HAI | None |
HA, haemagglutinin; HAI, haemagglutination inhibition; HD, high-dose; MOA; mode of action. Sources: European Centre for Disease Prevention and Control: seasonal influenza vaccines, CDC: United States influenza vaccines 2019–2020.